Marktanalyse - Myocardial Fibrosis - Pipeline Review, H2 2016

Global Markets Direct
12.2016
65 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Myocardial Fibrosis - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis — Pipeline Review, H2 2016, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 8 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Myocardial Fibrosis Overview 7

Therapeutics Development 8

Pipeline Products for Myocardial Fibrosis - Overview 8

Pipeline Products for Myocardial Fibrosis - Comparative Analysis 9

Myocardial Fibrosis - Therapeutics under Development by Companies 10

Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes 11

Myocardial Fibrosis - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Myocardial Fibrosis - Products under Development by Companies 14

Myocardial Fibrosis - Products under Investigation by Universities/Institutes 15

Myocardial Fibrosis - Companies Involved in Therapeutics Development 16

Daewoong Pharmaceutical Co Ltd 16

Evotec AG 17

Galectin Therapeutics Inc 18

GTx Inc 19

Invivosciences Inc 20

Lead Discovery Center GmbH 21

MandalMed Inc 22

miRagen Therapeutics Inc 23

Regulus Therapeutics Inc 24

Myocardial Fibrosis - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

Drugs for Tissue Fibrosis - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

DWN-10290 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

GMCT-01 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

GRMD-02 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

GTx-878 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

MGN-4220 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

NM-922 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

RG-012 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Inhibit Soluble Epoxide Hydrolase for Myocardial Fibrosis - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

SP-20102 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

TPI-2049 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Myocardial Fibrosis - Dormant Projects 62

Myocardial Fibrosis - Product Development Milestones 63

Featured News & Press Releases 63

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 63

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65





List of Tables

Number of Products under Development for Myocardial Fibrosis, H2 2016 8

Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Myocardial Fibrosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 16

Myocardial Fibrosis - Pipeline by Evotec AG, H2 2016 17

Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2016 18

Myocardial Fibrosis - Pipeline by GTx Inc, H2 2016 19

Myocardial Fibrosis - Pipeline by Invivosciences Inc, H2 2016 20

Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H2 2016 21

Myocardial Fibrosis - Pipeline by MandalMed Inc, H2 2016 22

Myocardial Fibrosis - Pipeline by miRagen Therapeutics Inc, H2 2016 23

Myocardial Fibrosis - Pipeline by Regulus Therapeutics Inc, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Myocardial Fibrosis - Dormant Projects, H2 2016 62





List of Figures

Number of Products under Development for Myocardial Fibrosis, H2 2016 8

Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 26

Number of Products by Stage and Targets, H2 2016 26

Number of Products by Mechanism of Actions, H2 2016 28

Number of Products by Stage and Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus